Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. (OPTHF) is a Canadian GMP-compliant pharmaceutical drug manufacturer focused on natural psilocybin and MDMA for regulated mental health therapies. News about Optimi often centers on its role in supplying psychedelic medicines for clinical trials, prescription programs, and specialized treatment pathways in markets such as Australia, Canada, and Israel.
Investors and observers following Optimi’s news flow can expect updates on regulatory milestones, such as Health Canada inspections and Drug Establishment License developments, as well as announcements related to product launches and exports of MDMA and psilocybin capsules. Recent releases have highlighted commercial availability of psilocybin capsules for treatment-resistant depression under Australia’s Authorized Prescriber Scheme, MDMA capsules for PTSD treatment programs, and selection as a supplier for a multicenter PTSD clinical trial sponsored by Sheba Medical Center in Israel.
Corporate news also includes financing transactions, private placements of convertible debentures, and agreements with market-making and investor relations firms. Optimi additionally reports on participation in investor conferences, board changes, and strategic relationships with partners such as Mind Medicine Australia and clinical service providers involved in psychedelic-assisted psychotherapy programs.
This news page aggregates these company-issued updates, giving readers a single view of Optimi’s progress in psychedelic drug manufacturing, its involvement in regulated mental health initiatives, and its capital markets activities. For those tracking developments in pharmaceutical-grade psychedelics and their integration into formal treatment frameworks, Optimi’s news provides insight into how the company positions its MDMA and psilocybin products within evolving regulatory and clinical environments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Optimi Health Corp. (OTCQX: OPTHF) has announced a significant long-term distribution agreement with Mind Medicine Australia to supply GMP-grade MDMA and psilocybin for therapeutic use in Australia. This follows the Australian government's reclassification allowing authorized psychiatrists to prescribe these substances for treatment-resistant conditions starting July 1, 2023. Key aspects include signed purchase orders for medical-grade substances manufactured under GMP protocols at Optimi's Health Canada licensed facility. This agreement represents Optimi's first international sales of these products, supporting the push for expanded access to psychedelic therapies in response to the mental health crisis.
Optimi Health Corp. has submitted a clinical trial application for a Phase I study to evaluate the safety of its natural psilocybin standardized extract and proprietary MDMA drug candidate in healthy therapists. This trial, conducted in collaboration with ATMA Journey Centers, is the first to compare the effects of both substances. The study aims to enroll 25 participants across five groups, assessing safety and physiological markers. The company aims to address the significant shortage of therapists trained in psychedelic therapy as it progresses towards commercialization.
Optimi Health Corp. has announced the successful production of its proprietary MDMA drug candidate, OPTI-MHCL, under Good Manufacturing Practices (GMP) at its facility in Princeton, British Columbia. The drug, which demonstrates a purity of over 99%, is intended for clinical trials and patient access through Health Canada’s Special Access Program and Australia’s Authorized Prescriber Scheme.
Optimi aims to meet the growing global demand for MDMA, particularly with advancements towards FDA approval for MDMA-assisted therapy for PTSD. This end-to-end manufacturing process positions Optimi as a significant supplier in the psychedelics market.